UK – Britain closes in on £500m COVID-19 vaccine deal with Sanofi/GSK

Sanofi and GlaxoSmithKline look set to agree a £500m deal with Britain for the supply of 60 million doses of a potential COVID-19 vaccine, according to a report from the Sunday Times.

Last month, French drugmaker Sanofi said that it expects to start clinical testing of its experimental coronavirus vaccine in September, several months earlier than planned. The company added that it could have the vaccine ready for emergency use by as early as January.

According to the Sunday Times report, Britain is considering agreeing an option to buy the vaccine if it proves effective in human trials, and would pay the £500m total in stages.

Sanofi is investigating two vaccine candidates, one of which uses GSK’s AS03 adjuvant and is based on Sanofi’s baculovirus expression system, already used in its quadrivalent flu vaccine. The other candidate, which Sanofi is developing with Translate Bio, leverages mRNA technology against the novel coronavirus disease…